Claims

1. Use of a composition comprising each of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid in the manufacture of a medicament for the treatment of Alzheimer's disease in a human subject having an MMSE score of 25 or less.

2. The use according to claim 1, wherein the medicament is a single composition comprising each of lutein, zeaxanthin, meso-zeaxanthin and at least one omega-3 fatty acid.

3. The use according to claim 1 or 2, wherein the said at least one omega-3 fatty acid comprises docosahexaenoic acid.

4. The use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid is provided as a fish oil component in the composition.

5. The use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid comprises at least two fatty acids.

6. The use according to any one of the preceding claims, wherein the omega-3 fatty acid comprises docosahexaenoic acid and eicosapentaenoic acid.

7. The use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid is provided as the free acid, as a salt or as a triglyceride.

8. The use according to claim 7, wherein the salt comprises a monocation.

9. The use according to claim 8, wherein the salt comprises a metal monocation.

10. The use according to any one of the preceding claims, wherein the composition/s is/are formulated to be suitable for oral consumption and is/are to be administered orally.

11. The use according to any one of the preceding claims, wherein the composition/s is/are to be administered at least three times a week.

12. The use according to any one of the preceding claims, wherein the composition/s is/are to be administered daily.

13. The use according to any one of the preceding claims, wherein the composition/s is/are in unit dose form.

14. The use according to claim 13, wherein each unit dose of composition comprises 10mgs meso-zeaxanthin, 10mgs lutein, 2mgs zeaxanthin, and 1gm fish oil.

15. The use according to claim 13, wherein each unit dose of composition comprises 15mgs meso-zeaxanthin, 5mgs lutein, 1mg zeaxanthin, and 1gm fish oil.

16. The use according to claim 13, wherein each unit dose of the composition comprises between 20mgs and 2grams of docosahexaenoic acid.

17. The use according to any of one of the preceding claims, wherein the composition/s further comprise one or more of the following: acidity regulators; anticaking agents including sodium aluminosilicate, calcium or magnesium carbonate, calcium silicate, sodium or potassium ferricyanide; antioxidants including vitamin E, vitamin C, and polyphenols; colorings including artificial colorings FD&C Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Red No. 3, Yellow No. 5 and Yellow No. 6; and natural colorings caramel, annatto, cochineal, betanin, turmeric, saffron, paprika; color retention agents; emulsifiers; flavours; flavour enhancers; preservatives; stabilizers; sweeteners and thickeners.

18. The use according to any one of the preceding claims, wherein the composition/s is/are in the form of a tablet or capsule.

19. The use according to any one of the preceding claims, wherein the composition/s is/are to be administered on a weekly or daily basis over a period of at least 6 months.

20. The use according to any of claims 1-18, wherein the composition/s is/are to be administered on a weekly or daily basis over a period of at least 12 months.

21. The use according to any one of the preceding claims, wherein the composition substantially consists of lutein, zeaxanthin, meso-zeaxanthin, at least one omega-3 poly-unsaturated fatty acid or corresponding salt or triglyceride, and a diluent, carrier or excipient.

22. The use according to claim 21, wherein the omega-3 poly-unsaturated fatty acid or corresponding salt or triglyceride is DHA or a salt or triglyceride of DHA.

23. The use according to any one of the preceding claims, wherein the composition comprises each of lutein, zeaxanthin, meso-zeaxanthin and DHA and/or EPA, the composition being formulated in unit dose form for daily oral administration, for use in preventing or retarding the progression of cognitive impairment in a subject already exhibiting one or more symptoms of Alzheimer's disease prior to administration of the composition.